Summary:
AIM ImmunoTech is facing delisting from the NYSE American due to its low stock price, but plans to appeal. Trading will transition to the Pink O
U.S. stocks traded lower this morning, with the Dow Jones index dipping more than 1,100 points on Friday. China unveiled a retaliatory 34% tariff on U.S. goods?...
ARMISTICE CAPITAL, LLC (Trades, Portfolio), a notable investment firm, recently executed a significant transaction involving AIM ImmunoTech Inc. On December 31,
Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Electe
Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Elected Kellner Group Reiterates Plan to Revitalize AIM, Accelerate Clinical Development and Restore Value for Stockholders
Incumbent Board's Claims of Progress Are Not Credible or Supported by DataAIM Maintains Relationship with CRO Co-Founded by a Convicted Felon Who Deceived Inves